Revenue
2018
2019
2022
2023
2024
2025
Achieve Life Sciences, Inc. (ACHV)
Price$8.49Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2023
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Research & development | $23.0M | $22.8M | $15.8M | $30.1M | $24.0M | $6.9M | $9.7M | $5.9M | $3.1M | $286,000 | $25.1M | $46.2M | $55.3M | $39.9M | $21.6M | $18.5M | $20.2M |
| Operating expenses | $54.9M | $39.1M | $27.3M | $40.8M | — | — | $16.5M | $12.8M | — | — | $36.9M | $56.6M | $65.2M | — | — | — | — |
| Operating income | −$54.9M | −$39.1M | −$27.3M | −$40.8M | — | — | −$16.5M | −$12.8M | — | — | — | — | — | — | — | — | — |
| EBITDA | −$53.6M | −$37.4M | −$26.7M | −$40.3M | — | — | −$16.3M | −$12.6M | — | — | — | — | — | — | — | — | — |
| Net income | −$54.6M | −$39.8M | −$29.8M | −$42.4M | −$33.2M | −$14.7M | −$16.4M | −$12.7M | −$10.6M | −$1.2M | −$828,000 | −$26.2M | −$31.8M | −$21.1M | −$14.7M | −$12.6M | −$5.5M |
| Basic EPSper basic share | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11.63 | -$128.00 | -$290.00 | -$434.00 | -$312.00 | -$302.00 | -$358.00 | -$190.00 |
| Diluted EPSper diluted share | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11.63 | -$128.00 | -$290.00 | -$434.00 | -$312.00 | -$302.00 | -$358.00 | -$190.00 |
Owners
Reported shareholders
7.41%of listed shares
Frazier Life Sciences Management, L.P.7.61M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Frazier Life Sciences Management, L.P. | 7.41%7.61M shares |
TPG GP A, LLC | 6.70%6.88M shares |
venBio Partners LLC | 5.76%5.91M shares |
Logos Global Management LP | 5.28%5.43M shares |
BlackRock, Inc. | 5.13%5.27M shares |
FRANKLIN RESOURCES INC | 4.82%4.95M shares |
Paradigm Biocapital Advisors LP | 4.82%4.95M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.03%4.14M shares |
Propel Bio Management, LLC | 3.93%4.03M shares |
MARSHALL WACE, LLP | 3.67%3.77M shares |
STATE STREET CORP | 2.87%2.95M shares |
Venrock Adviser, LLC | 2.68%2.75M shares |
Vivo Capital, LLC | 2.68%2.75M shares |
Jupiter Topco LLC | 2.68%2.75M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 2.16%2.22M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.01%2.06M shares |
Alyeska Investment Group, L.P. | 1.87%1.93M shares |
Simplify Asset Management Inc. | 1.39%1.43M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.39%1.43M shares |
LPL Financial LLC | 0.88%902.26K shares |
Percentages use 102.72M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 18, 2025Form 4 | Oki Mark KChief Financial Officer | SellCommon Stock | 50.1K | $2.92 | $146.2K | 127.9K |
| Sep 18, 2025Form 4 | Stewart Richard AlistairChief Executive Officer | SellCommon Stock | 129.5K | $2.92 | $378.1K | 228.9K |
| Sep 4, 2025Form 4 | Wan JerryPrincipal Accounting Officer | SellCommon Stock | 14.1K | $2.77 | $39.0K | 32.7K |
| Sep 4, 2025Form 4 | KING THOMAS BRAXTONDirector | SellCommon Stock | 139.9K | $2.77 | $387.4K | 315.1K |
| Sep 4, 2025Form 4 | JACOBS CINDYPresident & CMO | SellCommon Stock | 27.6K | $2.77 | $76.5K | 115.6K |